AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

NCBiotech and their coalition of partners received a $25 million Phase 2 award from the U.S. Economic Development Administration’s Build Back Better Regional Challenge. This award will further ...

The onset of the new U.S. presidential administration brings with it sweeping changes to U.S. policy related to artificial intelligence (AI). As a first step, the Trump administration revoked the ...

Discovering a new drug can reduce pain and suffering, preserve and extend life, and facilitate procedures like surgery and recovery through anesthesia and pain management. Collectively, effective ...

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering ...

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...